160 related articles for article (PubMed ID: 15297392)
1. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Milano MT; Haraf DJ; Stenson KM; Witt ME; Eng C; Mittal BB; Argiris A; Pelzer H; Kozloff MF; Vokes EE
Clin Cancer Res; 2004 Aug; 10(15):4922-32. PubMed ID: 15297392
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Brockstein B; Haraf DJ; Stenson K; Fasanmade A; Stupp R; Glisson B; Lippman SM; Ratain MJ; Sulzen L; Klepsch A; Weichselbaum RR; Vokes EE
J Clin Oncol; 1998 Feb; 16(2):735-44. PubMed ID: 9469365
[TBL] [Abstract][Full Text] [Related]
3. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
Milano MT; Vokes EE; Salama JK; Stenson KM; Kao J; Witt ME; Mittal BB; Argiris A; Weichselbaum RR; Haraf DJ
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1096-106. PubMed ID: 15752889
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Salama JK; Vokes EE; Chmura SJ; Milano MT; Kao J; Stenson KM; Witt ME; Haraf DJ
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):382-91. PubMed ID: 16213104
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Brockstein BE; Weichselbaum RR
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):70-6. PubMed ID: 10210543
[TBL] [Abstract][Full Text] [Related]
6. A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.
Brockstein B; Haraf DJ; Stenson K; Sulzen L; Witt ME; Weichselbaum RW; Vokes EE
Ann Oncol; 2000 Jun; 11(6):721-8. PubMed ID: 10942062
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study.
Benasso M; Merlano M; Sanguineti G; Corvò R; Numico G; Ricci I; Pallestrini E; Santelli A; Vitale V; Marchetti G; Rosso R
Am J Clin Oncol; 2001 Dec; 24(6):618-22. PubMed ID: 11801767
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.
Salama JK; Haraf DJ; Stenson K; Milano MT; Witt ME; Vokes EE
Cancer J; 2005; 11(2):140-6. PubMed ID: 15969989
[TBL] [Abstract][Full Text] [Related]
9. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
Seiwert TY; Haraf DJ; Cohen EE; Stenson K; Witt ME; Dekker A; Kocherginsky M; Weichselbaum RR; Chen HX; Vokes EE
J Clin Oncol; 2008 Apr; 26(10):1732-41. PubMed ID: 18375903
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Rosen FR; Haraf DJ; Kies MS; Stenson K; Portugal L; List MA; Brockstein BE; Mittal BB; Rademaker AW; Witt ME; Pelzer H; Weichselbaum RR; Vokes EE
Clin Cancer Res; 2003 May; 9(5):1689-97. PubMed ID: 12738722
[TBL] [Abstract][Full Text] [Related]
12. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Vokes EE; Stenson K; Rosen FR; Kies MS; Rademaker AW; Witt ME; Brockstein BE; List MA; Fung BB; Portugal L; Mittal BB; Pelzer H; Weichselbaum RR; Haraf DJ
J Clin Oncol; 2003 Jan; 21(2):320-6. PubMed ID: 12525525
[TBL] [Abstract][Full Text] [Related]
13. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
14. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Kies MS; Haraf DJ; Rosen F; Stenson K; List M; Brockstein B; Chung T; Mittal BB; Pelzer H; Portugal L; Rademaker A; Weichselbaum R; Vokes EE
J Clin Oncol; 2001 Apr; 19(7):1961-9. PubMed ID: 11283128
[TBL] [Abstract][Full Text] [Related]
15. Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study.
Halim AA; Wahba HA; El-Hadaad HA; Abo-Elyazeed A
Med Oncol; 2012 Mar; 29(1):279-84. PubMed ID: 21279703
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Loong HH; Winquist E; Waldron J; Chen EX; Kim J; Palma D; Read N; Razak AR; Diaz-Padilla I; Chan K; Bayley A; Hossain M; Wang L; Chin S; Siu LL; Hope A
Eur J Cancer; 2014 Sep; 50(13):2263-70. PubMed ID: 24953566
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of low-dose gemcitabine and radiation alternated to cisplatin and 5-fluorouracil: an active and manageable regimen for stage IV squamous cell carcinoma of the head and neck.
Benasso M; Vigo V; Bacigalupo A; Ponzanelli A; Marcenaro M; Corvò R; Margarino G
Radiother Oncol; 2008 Oct; 89(1):44-50. PubMed ID: 18423671
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Stathopoulos G; Nicolaides C; Kalogera-Fountzila A; Kalofonos H; Nikolaou A; Bacoyiannis C; Samantas E; Papadimitriou C; Kosmidis P; Daniilidis J; Pavlidis N
Ann Oncol; 1999 Apr; 10(4):475-8. PubMed ID: 10370793
[TBL] [Abstract][Full Text] [Related]
20. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Mick R; McEvilly JM; Weichselbaum RR
J Clin Oncol; 1994 Nov; 12(11):2351-9. PubMed ID: 7525886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
